Login
- Title:
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
- Document type:
- Article; Journal Article
- Author(s):
- Barbato, Francesco; Fendler, Wolfgang Peter; Rauscher, Isabel; Herrmann, Ken; Wetter, Axel; Ferdinandus, Justin; Seifert, Robert; Nader, Michael; Rahbar, Kambiz; Hadaschik, Boris; Eiber, Matthias; Gafita, Andrei; Weber, Manuel
- Abstract:
- Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework for disease volume assessment in mHSPC. Methods: Three PET centers screened their PSMA-PET database for mHSPC patients. CT versus PSMA-PET stage, lesion number, and classification of LVD vs. HVD were determined by one blinded reader; PSMA-positive tumor volume (PSMA-TV) was quantified semi-automatically. Results: 85 CT-based CHAARTED-LVD and 20 CT-based CHAARTED-HVD patients were included. A PSMA-TV of ~40 ml was the optimal cutoff between CT-based CHAARTED-LVD (non-unifocal) and HVD (non-M1c) (AUC 0.86). Stratification into PET-LVD (unifocal or oligometastatic/disseminated <~40 mL) and PET-HVD (oligometastatic/disseminated ≥~40 mL or M1c) had 13% misalignment with CHAARTED criteria. Conclusion: PSMA-PET criteria with volume quantification deliver comparable LVD/HVD discrimination with additional subgroups for unifocal, oligometastatic and disseminated disease, critical for guidance of targeted or multimodal therapy.
- Journal title abbreviation:
- J Nucl Med
- Year:
- 2021
- Journal volume:
- 62
- Journal issue:
- 12
- Pages contribution:
- 1747-1750
- Fulltext / DOI:
- doi:10.2967/jnumed.121.262120
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/33990403
- Print-ISSN:
- 0161-5505
- TUM Institution:
- Klinik und Poliklinik für Nuklearmedizin
BibTeX